Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- Humans (26)
- Child (20)
- Female (19)
- Male (18)
- Adolescent (17)
-
- Pediatric rheumatology (12)
- Pediatrics (12)
- Rheumatology (10)
- Arthritis, Juvenile (8)
- Surveys and Questionnaires (7)
- Antirheumatic Agents (6)
- Child, Preschool (6)
- Methotrexate (6)
- Young Adult (6)
- Adult (5)
- Children (5)
- Diagnosis (5)
- Juvenile idiopathic arthritis (5)
- Registries (5)
- United States (5)
- Africa (4)
- Feasibility Studies (4)
- Pain (4)
- Pilot Projects (4)
- Quality of Life (4)
- Retrospective Studies (4)
- Treatment Outcome (4)
- Arthritis (3)
- Consensus (3)
- Consensus treatment plan (3)
- Publication Year
- Publication
-
- Manuscripts, Articles, Book Chapters and Other Papers (37)
- Faculty, Staff and Students Publications (15)
- Journal Articles (6)
- Paediatrics and Child Health, East Africa (6)
- Posters (5)
-
- Faculty, Staff and Student Publications (2)
- Medicine Faculty Publications (2)
- Pediatrics Faculty Publications (2)
- Research Days (2)
- SOMA Faculty Publications (2)
- Tower Health Research Day (2)
- Department of Medicine Faculty Papers (1)
- Department of Paediatrics and Child Health (1)
- Department of Pediatrics Faculty Papers (1)
- Digital Journal of Clinical Medicine (1)
- Exercise Science Faculty Publications (1)
- Graduate Student Theses, Dissertations, & Professional Papers (1)
- HCA Healthcare Journal of Medicine (1)
- Journal of Maine Medical Center (1)
- Physician Assistant Scholarly Project Posters (1)
- Research Colloquium (1)
- Student Papers, Posters & Projects (1)
- Publication Type
Articles 91 - 92 of 92
Full-Text Articles in Rheumatology
Safety Of Celecoxib And Nonselective Nonsteroidal Anti-Inflammatory Drugs In Juvenile Idiopathic Arthritis: Results Of The Phase 4 Registry, R. E. Sobel, D. J. Lovell, H. I. Brunner, J. E. Weiss, P. W. Morris, B. S. Gottlieb, E. C. Chalom, L. K. Jung, K. B. Onel, E. H. Giannini, +6 Additional Authors
Safety Of Celecoxib And Nonselective Nonsteroidal Anti-Inflammatory Drugs In Juvenile Idiopathic Arthritis: Results Of The Phase 4 Registry, R. E. Sobel, D. J. Lovell, H. I. Brunner, J. E. Weiss, P. W. Morris, B. S. Gottlieb, E. C. Chalom, L. K. Jung, K. B. Onel, E. H. Giannini, +6 Additional Authors
Journal Articles
BACKGROUND: This study aimed to assess long-term safety and developmental data on juvenile idiopathic arthritis (JIA) patients treated in routine clinical practice with celecoxib or nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs). METHODS: Children aged >/=2 to-negative polyarthritis, persistent or extended oligoarthritis, or systemic arthritis were enrolled into this prospective, observational, multicenter standard-of-care registry. Eligible patients were newly or recently prescribed (
Randomized, Double-Blind, Placebo-Controlled Trial Of The Efficacy And Safety Of Rilonacept In The Treatment Of Systemic Juvenile Idiopathic Arthritis, N. T. Ilowite, K. Prather, Y. Lokhnygina, L. E. Schanberg, M. Elder, D. Milojevic, J. W. Verbsky, S. J. Spalding, B. S. Gottlieb, C. I. Sandborg, +12 Additional Authors
Randomized, Double-Blind, Placebo-Controlled Trial Of The Efficacy And Safety Of Rilonacept In The Treatment Of Systemic Juvenile Idiopathic Arthritis, N. T. Ilowite, K. Prather, Y. Lokhnygina, L. E. Schanberg, M. Elder, D. Milojevic, J. W. Verbsky, S. J. Spalding, B. S. Gottlieb, C. I. Sandborg, +12 Additional Authors
Journal Articles
OBJECTIVE: To assess the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in a randomized, double-blind, placebo-controlled trial. METHODS: An initial 4-week double-blind placebo phase was incorporated into a 24-week randomized multicenter design, followed by an open-label phase. Seventy-one children who had active arthritis in >/=2 joints were randomized (1:1) to the 2 arms of the study. Patients in the rilonacept arm received rilonacept (loading dose 4.4 mg/kg followed by 2.2 mg/kg weekly, subcutaneously) beginning on day 0. Patients in the placebo arm received placebo for 4 weeks followed by a loading dose of rilonacept at week 4 followed by …